Advertisement
Canada markets close in 2 hours 56 minutes

  • S&P/TSX

    21,855.75
    -17.97 (-0.08%)
     

  • S&P 500

    5,036.05
    -35.58 (-0.70%)
     

  • DOW

    38,023.19
    -437.73 (-1.14%)
     

  • CAD/USD

    0.7314
    +0.0016 (+0.22%)
     

  • CRUDE OIL

    82.56
    -0.25 (-0.30%)
     

  • Bitcoin CAD

    88,316.61
    -334.86 (-0.38%)
     

  • CMC Crypto 200

    1,390.61
    +8.03 (+0.58%)
     

  • GOLD FUTURES

    2,341.60
    +3.20 (+0.14%)
     

  • RUSSELL 2000

    1,972.12
    -23.31 (-1.17%)
     

  • 10-Yr Bond

    4.6960
    +0.0440 (+0.95%)
     

  • NASDAQ

    15,554.33
    -158.42 (-1.01%)
     

  • VOLATILITY

    16.47
    +0.50 (+3.13%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6809
    -0.0010 (-0.15%)
     
MARKETS LIVE BLOG:

STOCKS SLIDE AFTER META'S REALITY CHECK, DOWNBEAT GDP

Caterpillar sinks 7% after earnings, management sees weakness in Europe, Asia-Pacific

Cipher Pharmaceuticals Schedules Q1 2023 Earnings Release and Conference Call

CNW Group
·1 min read

MISSISSAUGA, ON, May 4, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the first quarter of 2023 on Thursday, May 11, 2023. The Company will also host a conference call on Friday, May 12, 2023 at 8:30am ET to discuss the results and corporate developments.

CONFERENCE CALL DETAILS

DATE:                                    Friday, May 12, 2023
TIME:                                     8:30 a.m. EDT
DIAL-IN NUMBER:                (416) 764-8650 or (888) 664-6383
CONFERENCE ID:                40452017
REPLAY DIAL-IN:                  (888) 390-0541 (playback 452017#)
                                               Expires May 19, 2022
WEBCAST:                             https://app.webinar.net/wOPDyeLaKb0

About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.

SOURCE Cipher Pharmaceuticals Inc.

Cision
Cision

View original content: http://www.newswire.ca/en/releases/archive/May2023/04/c9102.html